The historical rank and industry rank for JW (Cayman) Therapeutics Co's Net Margin % or its related term are showing as below:
JWCTF'
s Net Margin % Range Over the Past 10 Years
Min: -2280.5 Med: -441.74 Max: -195.54
Current: -195.54
JWCTF's Net Margin % is ranked worse than 60.25% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs JWCTF: -195.54
JW (Cayman) Therapeutics Co (OTCPK:JWCTF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
JW (Cayman) Therapeutics Co Net Margin % Related Terms
JW (Cayman) Therapeutics Co Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JWCTF vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JW (Cayman) Therapeutics Co Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's Net Margin % distribution charts can be found below:
* The bar in red indicates where JW (Cayman) Therapeutics Co's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JW (Cayman) Therapeutics Co (JWCTF) has a Net Margin % of -162.45% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on JW (Cayman) Therapeutics Co and its competitors. According to the industry distribution chart, JW (Cayman) Therapeutics Co ranks #570 out of 946 companies in the Biotechnology industry, placing it in the top 60.3%.
Is JW (Cayman) Therapeutics Co's Net Margin % too high?
JW (Cayman) Therapeutics Co's current Net Margin % is -162.45%. Based on the distribution chart, JW (Cayman) Therapeutics Co ranks #570 out of 946 companies in the Biotechnology industry, which is below the industry midpoint. Overall, JW (Cayman) Therapeutics Co has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does JW (Cayman) Therapeutics Co's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, JW (Cayman) Therapeutics Co ranks #570 out of 946 companies for Net Margin %. This places JW (Cayman) Therapeutics Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on JW (Cayman) Therapeutics Co and its competitors. JW (Cayman) Therapeutics Co's current Net Margin % is -162.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JW (Cayman) Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co (JWCTF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.57, compared to a current price of $0.24 — trading 58.3% below its estimated fair value. The current Net Margin % is -162.45%. JW (Cayman) Therapeutics Co's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For JW (Cayman) Therapeutics Co (JWCTF), the current Net Margin % is -162.45% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JW (Cayman) Therapeutics Co (JWCTF) Overvalued in 2026?
Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co stock appears to be undervalued.
The current stock price of $0.24 is trading 58.3% below its estimated GF Value™ of $0.57.
GuruFocus considers JW (Cayman) Therapeutics Co to be Possible Value Trap.
Key valuation signals for JWCTF:
Net Margin %: -162.45%
GF Value™: $0.57 vs. price of $0.24 (58.3% below fair value)
No single metric tells the full story. See the JWCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
30GF Score
Get the complete analysis for JWCTF
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JWCTF has been successfully added to your 
